Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

Clinical trial NCT06574347 · RECRUITING

Trial details

NCT number: NCT06574347
Sponsor: Avistone Biotechnology Co., Ltd.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non-Small-Cell Lung Cancer

Start date: 2024-08-07
Primary completion: 2026-10-31
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.